Waters and the Chinese Pharmacopoeia Commission (ChP) have teamed up to establish an Open Laboratory.  The facility is scheduled to open before the end of 2014 and would focus on research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods.

Both the ChP and Waters expect the laboratory to become one of the national technical support centers in the field of Chinese pharmaceutical standards.

"Our collaboration with the ChP will make positive contributions to assuring drug quality control in China.," said Art Caputo, President of the Waters Division.

At the collaboration agreement signing ceremony in Zhang Wei, Secretary General ChP Beijing, pointed out that the Joint Open Laboratory cooperation would become another milestone.  This cooperation not only meets the needs of ChP’s own development, but also meets the demands of enhanced pharmacopoeia standards and improved public drug safety."

Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new Joint Open Laboratory is more than 400 sq. m. The laboratory will be fitted with a full complement of Waters chromatography and mass spectrometry technologies, including a range of ACQUITY UPLC systems, ACQUITY UPC2 System, Xevo tandem quadrupole and time-of-flight mass spectrometers, and a Natural Products Application Solution with UNIFI.

The Chinese Pharmacopoeia Commission is an official compendium of drugs and has been in place since 1950 – publishing compendiums in 1953, 1963, 1977, 1985, 1990, 1995, 2000, 2005, and 2010. Formerly reporting under the Chinese Ministry of Health, it is now is an affiliated commission of the newly formed Chinese Food and Drug Administration (CFDA). The Chinese Pharmacopoeia Commission is also officially recognized by the World Health Organization.

Waters is known for its portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis. In 2013, the company clocked revenues of $1.9 billion.